论文部分内容阅读
目的:研究bcl-2硫代反义寡核苷酸(bcl-2ASODN)联合Rituximab[CD20单克隆抗体(mAb)]对B细胞淋巴瘤Raji细胞株体内外增殖和凋亡的影响,并探讨其作用机制。方法:bcl-2ASODN和Rituximab分别和联合作用B细胞淋巴瘤Raji细胞后,通过MTT法检测细胞生长情况;流式细胞术(FCM)检测bcl-2蛋白表达和细胞凋亡;RT-PCR检测bcl-2mRNA表达水平;用Raji细胞建立裸鼠B细胞淋巴瘤模型观察bcl-2ASODN与Rituximab联合在体内的抗肿瘤效果。结果:5~30μmol/L bcl-2和1~16mg/L Rituximab单独应用均能抑制Raji细胞生长、诱导细胞凋亡、使bcl-2蛋白和bcl-2mRNA表达降低,但两者联合应用较单独应用抑制作用更为明显(P<0.01)。体内实验表明,bcl-2ASODN与Rituximab联合应用较单独可有效抑制BALB/c裸鼠B细胞淋巴瘤的生长(P<0.01)。结论:bcl-2ASODN联合Rituximab较分别单独应用可明显抑制B细胞淋巴瘤Raji细胞生长,促进细胞凋亡;其机制可能是通过联合下调bcl-2蛋白及bcl-2mRNA表达而起作用。
AIM: To investigate the effect of bcl-2 ASODN combined with Rituximab [CD20 monoclonal antibody (mAb)] on the proliferation and apoptosis of B-cell lymphoma Raji cells in vitro and in vivo Mechanism. Methods: Bcl-2ASODN and Rituximab were used to detect the growth of Raji cells by MTT assay respectively. The expression of bcl-2 protein and apoptosis were detected by flow cytometry (FCM) and bcl-2 -2 mRNA expression level; using Raji cells to establish nude mouse B cell lymphoma model observed bcl-2ASODN combined with Rituximab antitumor effect in vivo. Results: Both Rituximab and 5 ~ 30μmol / L bcl-2 and 1 ~ 16mg / L Rituximab could inhibit the growth of Raji cells and induce the apoptosis of cells, and decrease the expression of bcl-2 protein and bcl-2 mRNA, Application inhibition is more obvious (P <0.01). In vivo experiments showed that the combination of bcl-2ASODN and Rituximab alone could effectively inhibit the growth of B-cell lymphoma in BALB / c nude mice (P <0.01). CONCLUSION: Bcl-2 ASODN combined with Rituximab can significantly inhibit the growth of B-lymphoma cells and promote the apoptosis of B-lymphoma cells, respectively. The mechanism may be related to the down-regulation of bcl-2 protein and bcl-2 mRNA expression.